Core Viewpoint - The company has announced its profit distribution plan for the fiscal year 2024, which includes a cash dividend of 0.50 RMB per 10 shares, totaling approximately 59.49 million RMB to be distributed to shareholders [1][2]. Summary by Sections Profit Distribution Plan - The profit distribution plan was approved at the annual shareholders' meeting held on May 15, 2025, with a total share capital of 1,189,712,382 shares as the basis for the distribution [1][2]. - The cash dividend of 0.50 RMB per 10 shares will be distributed to all shareholders, amounting to a total of 59,485,619.10 RMB (including tax) [1][2]. Implementation Details - The distribution will not include stock dividends or capital reserve transfers to increase share capital [1]. - The cash dividend will be subject to different tax rates for various categories of shareholders, with specific provisions for Hong Kong investors and domestic investors [2]. Key Dates - The record date for the distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [2][3]. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies or other custodial institutions [3]. Contact Information - For inquiries, shareholders can contact the company's securities department located in Chongqing, with provided contact details for further assistance [3].

2024年度权益分派实施公告 证券代码：300194 证券简称：福安药业 公告编号：2025-019 福安药业（集团）股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）2024 年年度权益分派 方案已获 2025 年 5 月 15 日召开的 2024 年年度股东大会审议通过，现将权益 分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、2025 年 4 月 23 日，公司第六届董事会第二次会议审议通过了《关于公 司 2024 年度利润分配预案的议案》，详细情况请见公司于 2025 年 4 月 24 日在 中国证监会指定信息披露网站上披露的《关于公司 2024 年度利润分配预案的公 告》。 公司于 2025 年 5 月 15 日召开 2024 年度股东大会，审议通过了《关于公 司 2024 年度利润分配方案的议案》。公司 2024 年度利润分配方案为：以公司现 有总股本 1,189,712,382 股为基数，向全体股东每 10 股派发现金股利 0.50 元人 民币（含税），共计派发现金股利 ...

上 海 东 方 华 银 律 师 事 务 所 C A P I T A L L A W & P A R T N E RS 上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 邮编：200336 电话：+86 21 68769686 Tel ：+86 21 68769686 传真：+86 21 68769686 Fax：+86 21 68769686 Building 34, Hongqiao Guesthouse, 1591 Hongqiao Rd., Shanghai，p.c: 200336 上海东方华银律师事务所 关于福安药业（集团）股份有限公司 法律意见书 致：福安药业（集团）股份有限公司 上海东方华银律师事务所（以下简称"本所"）接受福安药业（集团）股份 有限公司（以下简称"公司"或"福安药业"）委托，就公司召开 2024 年年度 股东大会（以下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）等法律、法规和其他规范性文件以及《福安药业（集团）股份有 限公司章程》（以下简称"《公司章程》"）的有关规定，就公司本次 ...

证券代码：300194 证券简称：福安药业 公告编号：2025-018 福安药业（集团）股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 特别提示： 1．本次股东大会无增加、变更、否决提案的情况； 2．本次股东大会不涉及变更以往股东大会已通过的决议； 3、本次股东大会对中小投资者的表决单独计票，中小投资者指单独或者合 计持有本公司 5%以上股份的股东以外的其他股东，且不包含持有公司股份的 公司董事、监事和高级管理人员； 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间：2025 年 5 月 15 日（星期四）下午 14:30 2、网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 15 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00；通过深圳 证券交易所互联网系统投票的具体时间为 2025 年 5 月 15 日上午 9:15 至下午 15:00 期间的任意时间。 出席本次会议的中小投资者 186 人，代表股份数 11,405,579 股 ...

Financial Performance - The company's 2024 consolidated revenue was CNY 2.391 billion, with a cost of CNY 1.125 billion [45] - The net profit contribution from Tianheng Pharmaceutical in 2024 was CNY 18.63 million, accounting for 6.7% of the company's net profit [2] - The company reported a significant profit decline, attributing it to centralized procurement, which has impacted profits by nearly half [4] Investment and Asset Management - The company invested USD 73 million in a U.S. project in 2019, equivalent to CNY 5.0297 billion at the time, but reported an impairment of CNY 6.23 billion in 2021 [16][25] - The impairment amount for the company's 51% stake in the U.S. project was CNY 3.18 billion, reflecting a significant difference from the total impairment [16][25] Shareholder Concerns - The company has faced criticism for stagnant dividends, which are determined based on sustainable development and performance [2] - There are ongoing concerns regarding stock price manipulation, with the company asserting that it operates normally and is not involved in any illegal activities [13][14] Strategic Initiatives - The company plans to enhance its market presence by focusing on non-centralized procurement products and optimizing its product structure [4] - Future goals include improving operational stability and governance in response to industry policy changes [33] Regulatory and Legal Issues - The company is currently involved in litigation related to its U.S. investment, with no preliminary judgment yet [40] - The company received administrative measures from the China Securities Regulatory Commission, which are being addressed through legal channels [14][32] Market Position and Future Outlook - The company aims to expand its international market presence while maintaining a primary focus on domestic operations [8] - The company is committed to improving investor relations and enhancing information disclosure to stabilize and boost its market value [15]

Core Viewpoint - The company is actively engaging in investor relations and is committed to improving its market value through various measures, including performance enhancement and cash dividends [2][5][6]. Group 1: Company Performance and Financials - The company's consolidated revenue for 2024 was 23.91 billion yuan, with a cost of 11.25 billion yuan [3]. - The company plans to optimize its cost structure and enhance revenue by expanding its market for non-collective procurement products and leveraging its new intelligent manufacturing facilities [3][11]. - The company acknowledges the impact of industry policies on its performance and aims to stabilize its operational results [2][5]. Group 2: Market Value Management - The company is focused on enhancing investor relations and improving information disclosure quality as part of its market value management strategy [2][5][6]. - The company has no current plans for share buybacks but emphasizes its commitment to maintaining market value through operational improvements and cash dividends [4][12]. - The company understands investor concerns regarding stock price fluctuations and is dedicated to addressing these issues within legal and regulatory frameworks [6][10]. Group 3: Legal and Regulatory Matters - The company is currently involved in a lawsuit in the United States related to its investment, with no preliminary judgment yet [4][9]. - The company received an administrative regulatory decision from the China Securities Regulatory Commission, which it is addressing through legal means [6][10]. Group 4: Research and Development - The company is primarily focused on chemical pharmaceuticals and is currently conducting clinical trials for its partnered projects [5][11]. - The company has not disclosed any innovative drugs for sale, focusing instead on its extensive line of chemical generic drugs [8][11].

Core Viewpoint - The pharmaceutical industry in China is undergoing significant policy changes, impacting the market landscape, with Fu'an Pharmaceutical demonstrating strong performance amidst these challenges, achieving a revenue of 2.391 billion yuan and a net profit of 280 million yuan in 2024, reflecting a year-on-year growth of 20.69% [1] Group 1: Company Overview - Fu'an Pharmaceutical, established in 2004 and listed in 2011, specializes in antibiotics and has built a strong competitive moat in the generic drug sector over 20 years [2] - The company has a comprehensive chemical pharmaceutical supply chain, covering drug research and development, intermediates, raw materials, and production, which positions it favorably in the changing industry landscape [2][3] Group 2: Product and R&D Competitiveness - Fu'an focuses on its core business, accumulating technical advantages and operational experience, leading to a diverse product range across various therapeutic areas [3] - The company has a stable sales team and network, actively participating in national procurement, with 13 products selected by the end of 2024, positively impacting overall performance [3][4] - R&D is a core competitive advantage, with a dedicated team responsible for various stages of drug development, and the R&D expense ratio has increased from 3.67% in 2020 to 6.41% in 2024, enhancing competitive positioning [4] Group 3: Financial Performance - Despite industry-wide revenue and profit fluctuations due to policy changes, Fu'an's revenue reached 2.391 billion yuan in 2024, only a slight decline of 9.68% [5] - The company maintained a high gross margin of 52.96% in 2024, with a significant reduction in sales expenses from 45.06% in 2020 to 23.56% in 2024, contributing to a net profit increase of 20.69% to 280 million yuan [6] - The net profit margin improved from 8.76% in 2023 to 11.7% in 2024, with a remarkable growth in non-recurring net profit by 14.68 times to 259 million yuan [6] Group 4: Market Dynamics and Future Outlook - The pharmaceutical manufacturing industry in China is expected to grow due to an aging population and increasing health awareness, with high-value products becoming key growth drivers [7] - Recent policy changes, including the implementation of the National Drug Standard Management Measures, are set to enhance drug quality and safety, benefiting companies like Fu'an that can adapt and innovate [7][8] - Fu'an has successfully participated in national procurement, with three products winning bids, while also expanding its market presence for non-procurement products to mitigate pricing pressures [9] Group 5: Strategic Development - Fu'an's approach to continuous improvement and innovation positions it well in a competitive market, demonstrating that opportunities for value re-evaluation exist even in mature sectors [10]

近期福安药业（300194）发布2025年一季报，证券之星财报模型分析如下： 经营业绩 近期福安药业发布的2025年一季报显示，公司业绩出现明显下滑。具体来看，截至本报告期末，公司营 业总收入为4.68亿元，同比下降42.22%；归母净利润为6904.9万元，同比下降43.63%；扣非净利润为 6568.48万元，同比下降43.8%。 单季度数据 主营分类 主营构成 主营收入 收入占比 主营利润 利润占比 毛利率 财务分析 业务评价 证券之星价投圈财报分析工具显示，公司去年的ROIC为5.36%，近年资本回报率一般。公司业绩具有周 期性。去年的净利率为11.63%，算上全部成本后，公司产品或服务的附加值一般。 从单季度数据来看，2025年第一季度营业总收入为4.68亿元，同比下降42.22%；归母净利润为6904.9万 元，同比下降43.63%；扣非净利润为6568.48万元，同比下降43.8%。 主要财务指标 本次财报公布的各项数据指标表现不尽如人意。具体如下： 主营收入构成 根据财报，福安药业的主营收入构成如下表所示： 融资分红 公司自上市以来，累计融资总额为34.66亿元，累计分红总额为6.05亿元，分 ...

证券代码：300194 证券简称：福安药业 公告编号：2025-009 福安药业（集团）股份有限公司 关于续聘公司 2025 年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日 召开第六届董事会第二次会议和第六届监事会第二次会议，分别审议通过了《关 于续聘公司 2025 年度审计机构的议案》，公司拟续聘永拓会计师事务所（特殊 普通合伙）（以下简称"永拓所"），为公司 2025 年度审计机构，聘期一年，并 提交公司 2024 年度股东大会审议通过后生效， 本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国有企 业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。现将 具体情况公告如下： 一、拟聘任会计师事务所的基本信息 1、基本信息 上年度末签署过证券服务业务审计报告的注册会计师人数：130 人 最近一年（2024 年度）收入总额（经审计）：32,267.90 万元 最近一年（2024 年度）审计业务收入（经审计）：26,948 ...

证券代码：300194 证券简称：福安药业 公告编号：2025-017 福安药业（集团）股份有限公司 关于为子公司申请银行授信融资提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、本次担保情况概述 福安药业（集团）股份有限公司（以下简称"公司"）全资子公司福安药业 集团庆余堂制药有限公司（以下简称"庆余堂"）、福安药业集团宁波天衡制 药有限公司（以下简称"天衡制药"）为保障公司正常生产经营需要，满足项 目建设及未来的流动资金需求，拟向商业银行申请融资授信额度，由公司、控 股股东汪天祥提供连带责任担保，具体融资额度及贷款时间视各公司具体业务 需求确定。申请授信额度具体情况如下： | 单位：万元 | | --- | | 公司名称 | 授信额度 | 银行名称 | 期限 | 担保人 | | --- | --- | --- | --- | --- | | 天衡制药 | 15000 | 建设银行股份有限公司宁波 | 5 年 | 公司 | | | | 市分行 | | | | 天衡制药 | 5000 | 中国银行股份有限公司镇海 | 年 3 | 公司 | ...